Breaking News | GenomeWeb

Breaking News

Speakers at the CVS meeting in Florida last week spoke about the utility and effectiveness of sequencing approaches in the study of viruses.

An international research team’s new rubber tree genome sequence could help tree growers learn more about how to optimize natural rubber production. 

The researchers also applied their database to impute alleles in the region linked to psoriasis.

Truncations to PD-L1's 3' untranslated region were detected in a variety of tumor types, apparently increasing expression of the gene and decreasing immune response to it.

With the conditional approval, Rosetta can now market its assays to test for key mutations in lung, colon, and melanoma cancers in New York State.

Last week, GenomeWeb's readers were most interested in a complaint accusing Myriad Genetics of violating HIPAA.

Altona has validated the test on various PCR platforms, and it is now authorized for use as a molecular diagnostic on patient samples. 

The firm could begin to see its product sales increase following the FDA's approval of its colorectal cancer screening test in April.

The company raised its offer to $1.70 per share from its previous agreement of $1.35 per share in response to an unsolicited bid from a third party.

The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.

The company said the proceeds of the round would be used to support the ongoing development of its urine-based bladder cancer test Bladder EpiCheck.

Elaine Mardis, Richard Wilson

The recruitment of Rick Wilson and Elaine Mardis from Washington University in St. Louis was made possible by a new $10 million gift from the Nationwide Foundation.

The firm will look for metabolic profiles that could help diagnose asphyxia in human newborns, signatures that were derived from animal studies.

Noridian proposes to cover several biomarker tests for guiding chemotherapy decisions for breast cancer patients with node-negative disease but not when it's node positive.

The Rutherford, NJ-based cancer molecular diagnostics firm will use the proceeds for general corporate purposes.

The Buffalo, NY-based firm will use the proceeds to grow its marketing, automation, and operations, and to launch additional molecular diagnostic products.

Four patients still want the government to investigate their allegations against Myriad, even though the firm complied with their data request at the last hour.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

The two organizations signed a memorandum of understanding this week, following the opening of the BGI-VPC Joint Research Laboratory in 2014.

A genome-wide association study involving nearly 6,000 individuals identified variants linked to nose-related features and chin protrusion in Latin Americans.

A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.

First quarter revenues jumped sharply as Rosetta benefitted from the urologic cancer testing services operations from PersonalizeDx.

Pages

In PLOS this week: canine GWAS of skeletal syndromes, Chagas disease outcomes and genetic ancestry, and more.

A team describes its idea for a clinical trial data-sharing database, called Vivli, ScienceInsider reports.

One case illustrates how DNA evidence can incriminate an innocent person, Scientific American says.

A lack of stability in research funding drives researchers away from academia, researchers write at eLife.